Tumor-stromal crosstalk also plays a role in resistance to therapies where CAF-dependent ECM remodeling provides a therapeutic “safe-haven” for BRAF mutant melanoma from the BRAF inhibitor PLX4720 (122). This evidence concerns the gene BRAF and neoplasm.